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Boca Raton Regional Hospital
•

Not-for-profit 400 bed advanced academic tertiary medical center

•

Recognized leader in:
– Cardiovascular Care
– Oncology
– Women’s Health
– Orthopedics
– Emergency Medicine
– Neurosciences

•

Predominantly elderly patient population

•

Highest ranked hospital in Palm Beach County
– Listed by U.S. News & World Report 2019-2020

•

Lynn Cancer Institute is one of the largest cancer programs in the state of Florida and
accredited by the American College of Surgeons

Presentation Objective
Assess the risk of acute kidney injury in
patients receiving vancomycin plus
piperacillin-tazobactam compared to
vancomycin plus cefepime

Background
• Vancomycin is a commonly used antibiotic to cover
methicillin-resistant Staphylococcus aureus (MRSA)
• It is often used in combination with broad spectrum
antibiotics such as piperacillin-tazobactam or cefepime
for empiric therapy in commonly encountered hospital
infections

Background
• The mechanism by which vancomycin causes renal injury
is not well understood. Accumulation of vancomycin in the
proximal renal tubule may lead to acute tubular necrosis
and glomerular destruction.1
• Semisynthetic penicillins, such as piperacillin, exhibit high
concentrations throughout the nephron and mechanism
of nephrotoxicity is likely acute interstitial nephritis.1
1. Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis.
2017;64(5):666-674.

Primary Literature
Trial

Outcome
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Hammond D. A. et al. Clin
Infect Dis. 2017;64(5):666674

The primary outcome was
incidence of AKI

Concomitant vancomycin and piperacillintazobactam was associated with increased
risk of AKI (OR 3.12; 95% CI, 2.04-4.78; P
<0.001)

Luther M. K. et al. Crit
Care Med 2018; 46:12-20

The primary outcome was AKI, as
defined by the individual study
(AKIN, RIFLE, KDIGO)

•

•

Vancomycin plus piperacillintazobactam vs vancomycin
monotherapy (OR, 3.40; 95% CI, 2.57–
4.50)
Vancomycin plus cefepime or
carbapenem vs vancomycin plus
piperacillin-tazobactam (OR, 2.68; 95%
CI, 1.83–3.91)

KDIGO – AKI Definition
Stage

Serum creatinine

Urine output

1

1.5 – 1.9 times baseline OR
≥ 0.3 mg/dL increase

< 0.5 mL/kg/hour for 6 – 12
hours

2

2 – 2.9 times baseline

< 0.5 mL/kg/hour for ≥ 12
hours

3

3 times baseline OR
Increase in serum creatinine to ≥ 4 mg/dL
OR
Initiation of renal replacement therapy OR,
In patients < 18 years, decrease in eGFR
to < 35 mL/min/1.73 m2

< 0.3 mL/kg/hour for ≥ 24
hours OR
Anuria for ≥ 12 hours

Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:179–184.

Purpose
Compare the incidence of acute kidney injury in
patients receiving vancomycin plus piperacillintazobactam compared to vancomycin plus
cefepime in our institution

Methods
Retrospective, single center, observational study

Conducted between January 1st, 2019 and December
31st, 2019
Patients were identified by a computer-generated
report through Discern Analytics Reporting Portal
Program

Statistical Analysis

N-1 Chi-squared test was used for
evaluation of nominal data
Comparison between continuous data
was performed using Student’s t test

Inclusion and Exclusion Criteria
Inclusion
• Patients ≥ 18 years of age
• Patients on vancomycin plus piperacillin-tazobactam or vancomycin plus
cefepime for more than 48 hours

Exclusion
•
•
•
•

Patients already experiencing an AKI
Patients with stage 4 CKD
Patients on renal replacement therapy
Patients with allergies to any of the study medications

Study Outcomes
Primary Endpoint
• The incidence of acute
kidney injury in patients
receiving vancomycin
plus piperacillintazobactam compared
to vancomycin plus
cefepime

Secondary Endpoints
• Length of hospital stay
• Increase in creatinine
to 2 times baseline
• Nephrology consult
after AKI

Results

1081 patients
screened for
inclusion

147 met inclusion
criteria

75 patients in
vancomycin plus
piperacillintazobactam

72 patients in
vancomycin plus
cefepime

933 excluded

Baseline Characteristics
Characteristics
Male sex
Age (years)
Baseline SCr (mg/dL)
ICU
Duration of antibiotic
therapy (days)
Comorbidities
CDK
Diabetes
COPD
CHF
Malignancy

vanc/pip-tazo
(n=75)

vanc/cef
(n=72)

P value

39 (52%)
67.3 ± 19.59
0.91 ± 0.3
12 (16%)

38 (53%)
71.03 ± 15.17
0.9 ± 0.9
10 (14% )

0.93
0.19
0.92
0.72

5.6 ± 2.5

5.3 ± 2.6

0.45

6 (8%)
15 (20%)
10 (13%)
6 (8%)
17 (23%)

5 (7%)
13 (18%)
6 (8%)
2 (3%)
25 (35%)

0.81
0.76
0.33
0.16
0.11

ABBREVATIONS: CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; CHF, chronic heart failure; vanc, vancomycin; pip-tazo,
piperacillin-tazobactam; cef, cefepime

Primary Type of Infection
Type
Bacteremia
Cellulitis
Other*
Osteomyelitis
Pneumonia**
Sepsis-empiric
SSTI

vanc/pip-tazo
(n=75)

vanc/cef
(n=72)

P value

4 (5%)
13 (17%)
9 (12%)
2 (3%)
36 (48%)
10 (13%)
1 (1%)

2 (3%)
14 (19%)
14 (19%)
4 (6%)
21 (29%)
15 (21%)
3 (4%)

0.44
0.74
0.22
0.38
0.02
0.23
0.29

*Meningitis, neutropenic fever, UTI, joint infection, other
**HAP/VAP, CAP, Aspiration pneumonia

ABBREVATIONS: SSTI, skin and soft tissue infection; vanc, vancomycin;
pip-tazo, piperacillin-tazobactam; cef, cefepime

Concomitant Nephrotoxic Medications
vanc/pip-tazo
(n=75)

vanc/cef
(n=72)

P value

13 (17%)

10 (13%)

0.57

1 (1%)

1 (1%)

1.00

21 (28%)

13 (18%)

0.15

NSAIDs

3 (4%)

5 (7%)

0.43

Vasopressors

4 (5%)

4 (6%)

1.00

Radiocontrast media

3 (4%)

0 (0%)

0.09

Medication
ACEi/ARB
Acyclovir
Loop diuretics

ABBREVATIONS: vanc, vancomycin; pip-tazo, piperacillin-tazobactam; cef,
cefepime; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II
receptor blocker; NSAID, nonsteroidal anti-inflammatory

Primary Outcome
P-value 0.04
% of patients with AKI

35

29.3%

30

25

20

15.3%
15

10

5

0

VANC/CEF
VANC/PIP-TAZO

Secondary Outcomes

Outcome

vanc/pip-tazo
(n=75)

vanc/cef
(n=72)

P value

Length of hospital stay (days)

14.28 ± 17.9

11.76 ± 9.2

0.28

6 (8%)

0 (0%)

0.02

2/22 (9%)

0/11 (0%)

0.54

SCr ≥ 2 times baseline
Nephrologist consult

ABBREVATIONS: vanc, vancomycin; pip-tazo, piperacillin-tazobactam; cef, cefepime

Conclusion
• This study showed that concomitant use of vancomycin
plus piperacillin-tazobactam puts patients at an increased
risk for AKI
• The severity of AKI was worse in the vancomycin plus
piperacillin-tazobactam group compared to vancomycin
plus cefepime group
• Clinicians should be aware of this potential risk and be
cautious when prescribing this regimen

Limitations

Retrospective observational study
Single center
Small sample size

Self-Assessment Question
The use of vancomycin plus piperacillin-tazobactam is
associated with an increased risk of acute kidney injury
a. TRUE
b. FALSE

Acknowledgment

Kristin Boyar, Pharm.D., BCPS

Risk of acute kidney injury in patients
receiving vancomycin and piperacillintazobactam compared to vancomycin and
cefepime
Viktoria Andonova, Pharm.D.
PGY1 Pharmacy Resident
Boca Raton Regional Hospital
Baptist Health South Florida
VAndonova@brrh.com

